No profile data available.
Actinium Pharmaceuticals, Inc. (ATNM) is a healthcare company in the blood cancer treatment drugs industry, based in New York, United States, with about 27 full-time employees.
It reported revenue of $90,000 for fiscal year 2025, and net income of -$33.89 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $35.00 million. Its market capitalization was $34.59 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.
Actinium Pharmaceuticals reported $90,000 in revenue for fiscal year 2025. In Q2 2026 revenue was $35.00 million.
$34.59 million as of October 9, 2026.
Listed companies of a similar size in the same industry (blood cancer treatment drugs) include Citius Oncology, Inc. (CTOR), Apollomics, Inc. (APLM), Lite Strategy, Inc. (LITS), Estrella Immunopharma, Inc. (ESLA).